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Abstract
Introduction:

While the endogenous first-phase insulin response has disappeared by the time of diagnosis of type 1 diabetes
mellitus (T1DM), anecdotal evidence suggests that these patients can continue to have a second-phase insulin
response during the first 12 months after diagnosis. We hypothesized that patients who are started on continuous
subcutaneous insulin infusion (CSII) at the time of diagnosis of T1DM would have a lower basal insulin
requirement than the 40–60% usually expected.

Methods:

We analyzed 38 patients with T1DM, age 9.9 ± 6.4 years, 71% male, who were started on CSII within the first
month of diagnosis.

Results:

Average basal insulin requirements were 47–49% of total daily dose during the first 12 months after diagnosis and
decreased from 0.30 U/kg/day at diagnosis to 0.20 U/kg/day by 12 months. Baseline percentage of basal insulin
was significantly correlated with hemoglobin A1c at baseline and at six months. The percentage of basal insulin
requirement at 12 months after diagnosis was significantly correlated with baseline body mass index (BMI) and
current BMI. No other correlations between percentage of basal insulin requirements and any other factors were seen.

Conclusion:

Our data suggest that, even though some endogenous insulin production remains during the first year
after diagnosis of T1DM, the distribution of basal versus total daily insulin requirements remains the same as in
the general population of people with diabetes. There may be benefits to starting patients on a higher basal rate
at time of diagnosis for overall glycemic control during the first six months. Further research is needed to
optimize starting insulin doses to maximize their potential in preserving beta-cell function.
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Author Affiliations: 1Maimonides Medical Center, Department of Pediatric Endocrinology, Brooklyn, New York; 2Children’s Hospital at
SUNY Downstate, Department of Pediatrics, Brooklyn, New York; 3Animas Corporation, West Chester, Pennsylvania; and 4BioSeek Endocrine Clinics,
New York, New York
Abbreviations: (AUC) area under the curve, (BG) blood glucose, (BMI) body mass index, (CSII) continuous subcutaneous insulin infusion,
(HbA1c) hemoglobin A1c, (MMTT) mixed meal tolerance test, (T1DM) type 1 diabetes mellitus, (TDD) total daily dose
Keywords: basal insulin production, basal insulin requirements, continuous subcutaneous insulin infusion, insulin pump, type 1 diabetes mellitus
Corresponding Author: Neesha Ramchandani, P.N.P., C.D.E., Maimonides Medical Center, Department of Pediatric Endocrinology, 977 48th Street,
Brooklyn, NY 11219; email address NRamchandani@maimonidesmed.org
610

Basal Insulin Requirements on Continuous Subcutaneous Insulin Infusion
During the First 12 Months After Diagnosis of Type 1 Diabetes Mellitus

Ramchandani

Introduction

I

In patients with established T1DM, the daily basal insulin
requirement is generally expected to be in the range of
40–60% of the total daily insulin dose.10,11 However, in
light of persisting second-phase insulin secretion early in
the course of T1DM, individuals who are started on CSII
at the time of diagnosis of T1DM should theoretically
require less exogenous basal insulin than individuals
with long-standing diabetes. Alternatively, these individuals
may have lower bolus insulin requirements and therefore
be on a higher percentage of basal insulin, because part
of the endogenous bolus feature is preserved. This study
was designed to test this hypothesis and to find what
factors, if any, were associated with these individuals’
exogenous basal insulin requirements.

nsulin secretion in healthy individuals without diabetes
is characterized by continuous basal secretion with peaks
that occur soon after meals.1 Basal insulin secretion is
the amount of insulin secreted in the fasting state in the
absence of exogenous stimuli.2 It has been estimated that
50% of the total insulin secreted by a healthy pancreas
is secreted under basal conditions.3 Stimulated insulin
secretion, which comprises the remaining 50%, occurs
in response to exogenous stimuli such as ingested meals.
Glucose is the most potent stimulant of insulin release.
When the glucose concentration in an individual is
increased suddenly, an initial short-lived burst of insulin
release occurs (first-phase insulin response); if the glucose
concentration is held at this level, the insulin release
gradually falls off and then begins to rise again to a
steady level (second-phase insulin response).2

Research Design and Methods

The amount of insulin produced by a lean, healthy
individual is usually between 18 and 40 U/day or
0.2–0.5 U/kg/day. Because half of this amount is
secreted in the basal state while the other in response
to meals, the basal insulin secretion is about 0.5–1.0 U/h.
After meal ingestion, insulin secretion rapidly increases
to up to six times the baseline secretion in response
to the oral glucose load and reaches a peak within
60 minutes.3,4
In type 1 diabetes mellitus (T1DM) there is a marked
deficiency of beta-cell mass. Prior to the development
of diabetes, there is a prolonged period when the autoimmune disease is thought to be active. During this
latent period, a progressive decline in first-phase insulin
secretion has been documented, as well as an impairment
in insulin pulses. By the time of clinical presentation
of T1DM, 90% of beta cells have been lost, although
some capacity for endogenous insulin secretion remains.
The endogenous insulin production rapidly declines over
the next two years after diagnosis.5
However, clinical evidence has shown that individuals
with T1DM can continue to have a second-phase insulin
response during the first 12 months after diagnosis.
In the same way, it has been repeatedly demonstrated
that treatment with continuous subcutaneous insulin
infusion (CSII), or insulin pumps, approximates normal
insulin physiology better than multiple daily injections
of short- and long-acting insulin and is the more logical
mode of treatment for T1DM.6–9
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This study is part of a larger study that was designed
to examine the feasibility and effects of starting children
and young adults on insulin pumps from the time of
diagnosis of T1DM.6 Subjects were recruited for this
12-month prospective study from two major medical
centers in New York City. Patients and their families
were approached during the initial hospitalization or an
outpatient visit soon after being diagnosed with T1DM to
inquire if they wanted to participate in a research study.
The clinicians who approached these patients ensured
that the families had time to absorb the diagnosis of
T1DM before discussing the study with them. Both the
patient and their family were educated about diabetes,
and the physician explained the rationale of starting
pump therapy early. Upon agreeing to participate in the
study, subjects and their families were taught insulin
pump mechanics and troubleshooting, and carbohydrate
counting was discussed with a nutritionist. Inpatients
(n = 12) were started on loaner insulin pumps with
lispro insulin immediately upon completion of learning
pump mechanics and troubleshooting, while outpatients
(n = 26) were started on loaner insulin pumps filled
with saline, which they wore for one week to become
comfortable with CSII before filling the pump with
lispro insulin.
Initial follow-up was done via daily phone calls to a
designated member of the diabetes team for the first
few days. Further follow-up included weekly phone
calls to the diabetes provider for blood glucose (BG)
management and troubleshooting lifestyle issues.
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The loaner pumps were replaced by subjects’ own
pumps upon receipt of the latter. Every subject was seen
in the office for a follow-up visit one month after the
initiation of CSII and once every three months thereafter,
or more often if needed.
To measure endogenous insulin production, a 3 hour
mixed meal tolerance test (MMTT) was performed in
28 subjects at baseline, 6 months, and 12 months after
diagnosis. Subjects’ pumps were disconnected at the
6- and 12-month MMTTs 4 h prior to the scheduled
start of the MMTT to minimize the suppressive influence
of exogenous insulin on endogenous insulin production.
In case of extremely high blood sugars and moderate or
large ketones, the MMTT could be stopped at the discretion
of the researchers. No MMTT had to be stopped because
of ketosis. Blood glucose excursions during the MMTT
were calculated as BGpeak – BGt = 0. C-peptide values were
analyzed looking at the area under the curve (AUC).

On the 3-hour MMTT, the BG measurements peaked at
90 minutes and then decreased. However, none of the
differences observed after the 90-minute time point
achieved statistical significance. The BG excursions at 0, 6,
and 12 months were 176, 134, and 132 mg/dl, respectively
(p = not significant). The BG measurements on MMTT
are depicted in Figure 1. Additionally, C-peptide AUC
values during the MMTTs did not significantly differ
during the first 12 months after diagnosis (C-peptide
AUCbaseline = 267 ± 363 ng/dl, C-peptide AUC6 months =
110 ± 94 ng/dl, C-peptide AUC12 months = 312 ± 364 ng/dl,
p = not significant between all time points).6

The data were analyzed using both Statistical Package
for the Social Sciences and Microsoft Excel for calculating
demographic data, mean and standard deviations, unpaired
two-tailed t-tests, and correlations (Pearson correlation
coefficients).

Table 1.
Demographic Data

Results
Thirty-eight patients (27 males, 11 females) were started
on CSII within one month of diagnosis of T1DM.
The subjects ranged in age from 1 to 32 years old, with
a mean age of 9.9 ± 6.4 years. Hemoglobin A1c (HbA1c)
decreased to 6.6 ± 1.1% by three months after diagnosis
and continued to stay at levels indicative of good glycemic
control throughout the study. Demographic variables of the
study population are presented in Table 1. The majority
of patients (68%) were treated on an outpatient basis
when diagnosed.

N

38

Male
Female

71% (n = 27)
29% (n = 11)

Age at diagnosis
(range)

9.9 ± 6.4 years
(1.3–32.3 years)

Ethnicity

Caucasian:
25 (66%)
Hispanic:
8 (21%)
Black:
1 (3%)
Asian:
1 (3%)
Middle Eastern: 1 (3%)
Other:
2 (5%)

Table 2.
Hemoglobin A1c, Insulin Requirements, and Body
Mass Index Over Time

Basal insulin requirement as a percentage of total daily
dose (TDD) was found to stay relatively constant during
the first 12 months after diagnosis and averaged 47–49%
of the TDD (range = 16–100%, p = not significant between
values at 0, 6, and 12 months). Total daily dose expressed
in units per kilogram also did not decrease significantly
during this time period. However, the absolute basal
insulin requirements decreased from 0.30 U/kg/day at
the time of diagnosis to 0.20 U/kg/day by 12 months
(p = .05; p = not significant between other time points)
(Table 2).
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The percentage of basal insulin at baseline inversely
correlated with HbA1c at baseline (r = -0.513, p = .01)
as well as six months after diagnosis (r = -0.501, p = .03).
A higher body mass index (BMI) at baseline and at
12 months was significantly correlated with higher
basal insulin requirements at 12 months after diagnosis
(r = 0.636, p < .05 and r = 0.651, p = .04, respectively).
No significant correlations were noted between basal
insulin requirements and age at diagnosis, HbA1c, weight,
BMI, or total exogenous insulin requirements.

0 months

6 months

12 months

10.9 ± 2.3

6.6 ± 1.2

7.4 ± 1.8

TDD U/kg/day

0.55 ± 0.25

0.46 ± 0.22

0.50 ± 0.19

Basal U/kg/day

0.30 ± 0.16

0.24 ± 0.13

0.20 ± 0.11

48 ± 6%

49 ± 20%

47 ± 23%

20.0 ± 6.4

19.6 ± 4.7

22.0 ± 7.1

HbA1c (%)

Basal as percentage
of TDD
BMI (kg/m2)
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Discussion
The hypothesis that the presence of endogenous insulin
secretion would cause a lower exogenous basal insulin
requirement did not hold true in this study, nor was a
decrease in the amount of bolus insulin as a percentage
of TDD observed. Despite being in honeymoon and
having evidence of endogenous insulin secretion during
the first 12 months of follow-up that was not significantly
different than the amount that existed at the time of
diagnosis of T1DM,6 the subjects in this study required
roughly the same percentage of exogenous basal insulin
as do people with longstanding diabetes.10,11 It is presumed
that the basal insulin requirements observed are actual
basal requirements, as most subjects’ BG levels were
within normal limits and very rarely rose above 140 mg/dl
(7.8 mmol/liter) during the first 12 months after diagnosis.
Correction boluses had to be given so infrequently that
subjects involved in this study often did not remember
what their insulin sensitivity factor was. Other researchers
have found basal insulin requirements to be as low
as 20–30% of TDD in pediatric patients on CSII.11,12
However, their results are based on cross-sectional data
from subjects of varying durations of T1DM. No other
study that has been done to date specifically describes
insulin requirements in children specifically with newonset T1DM. It is unknown if our study population
differs from the subjects in the aforementioned studies
in regards to the postprandial glycemic rise or AUC,
as this information is not available for comparison.
The decrease in exogenous basal insulin requirements
that was observed during the course of this study may
be due to reversal of the initial glucose toxicity that
occurs when T1DM presents. However, since the basal
insulin requirements were not significantly different
from baseline until 12 months after diagnosis, this
is likely not the case. Rather, the improvement may
be indicative of a slow recovery of beta-cell function.
A more detailed prospective study should be done to
determine the physiological factors associated with our
observations.

Various large studies, including the Diabetes Control and
Complications Trial, have demonstrated the efficacy
of CSII in lowering HbA1c and improving metabolic
control, including in the pediatric population, without
increasing the risk for hypoglycemia.13–19 Additionally, the
Epidemiology of Diabetes Interventions and Complications
study showed that good control achieved early in the
course of the disease has better long-term outcomes than
achieving good control later on, even if this degree of
glycemic control is not able to be maintained over time.18
The findings from our study support the same trend
toward initiating CSII soon after diagnosis of diabetes.
Additionally, in this particular cohort of patients, a
significant correlation was noted between a higher exogenous basal insulin dose and lower HbA1c at diagnosis
and six months later. As has also been found by others
in subjects with type 2 diabetes mellitus, this inverse
correlation suggests that the use of a higher basal insulin
infusion at diagnosis may be beneficial for achieving
better glycemic control during the first six months after
diagnosis.20,21 The beneficial effects of this initial intensive
therapy have the potential to persist for several years
afterward, even if glycemic control should worsen over
time.18 However, these benefits do not last indefinitely.19
Further research needs to be done to determine the
impact of good glycemic control right from the time
of diagnosis on the incidence of diabetes complications in
the future.

The results of the MMTT, specifically, automatically
decreasing BG after the 90-minute time point in the
3-hour test, were also suggestive of a second-phase insulin
response. However, given the results, it appears possible
that the apparent glycemic improvement may have been
caused by glucose decay rather than endogenous insulin
secretion, or perhaps by a combination of the two.
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Figure 1. Average BG values during 3-hour MMTTs.
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Conclusion
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